Empowered Funds LLC Invests $1.52 Million in Keros Therapeutics, Inc. $KROS

Empowered Funds LLC purchased a new stake in Keros Therapeutics, Inc. (NASDAQ:KROS) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 142,151 shares of the company’s stock, valued at approximately $1,521,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. AQR Capital Management LLC acquired a new stake in shares of Keros Therapeutics during the 1st quarter worth approximately $226,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Keros Therapeutics by 15.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,166 shares of the company’s stock worth $227,000 after acquiring an additional 2,982 shares during the period. Goldman Sachs Group Inc. grew its position in Keros Therapeutics by 38.3% in the first quarter. Goldman Sachs Group Inc. now owns 740,606 shares of the company’s stock worth $7,547,000 after acquiring an additional 205,022 shares during the period. Creative Planning increased its stake in Keros Therapeutics by 40.2% during the second quarter. Creative Planning now owns 24,226 shares of the company’s stock worth $323,000 after acquiring an additional 6,948 shares during the last quarter. Finally, Rhumbline Advisers increased its stake in Keros Therapeutics by 16.0% during the second quarter. Rhumbline Advisers now owns 51,815 shares of the company’s stock worth $692,000 after acquiring an additional 7,146 shares during the last quarter. 71.56% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, insider Lorena Raquel Lerner sold 3,568 shares of the business’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $10.29, for a total value of $36,714.72. Following the completion of the transaction, the insider directly owned 27,559 shares of the company’s stock, valued at $283,582.11. The trade was a 11.46% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders sold 5,893 shares of company stock worth $60,507. Insiders own 12.60% of the company’s stock.

Keros Therapeutics Trading Down 1.1%

Shares of Keros Therapeutics stock opened at $11.11 on Friday. The stock has a market cap of $220.31 million, a price-to-earnings ratio of -3.00 and a beta of 1.01. Keros Therapeutics, Inc. has a 12-month low of $9.69 and a 12-month high of $22.55. The company has a fifty day simple moving average of $10.80 and a 200-day simple moving average of $11.40.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings results on Monday, August 3rd. The company reported ($1.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.34) by ($0.11). Keros Therapeutics had a negative net margin of 256.60% and a negative return on equity of 21.40%. On average, analysts forecast that Keros Therapeutics, Inc. will post -5.27 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

KROS has been the topic of several recent analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Keros Therapeutics in a report on Wednesday, August 12th. Wells Fargo & Company cut their target price on shares of Keros Therapeutics from $20.00 to $18.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 4th. Wall Street Zen raised shares of Keros Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Monday, August 24th. HC Wainwright restated a “buy” rating and issued a $20.00 price target on shares of Keros Therapeutics in a research note on Tuesday, August 4th. Finally, Leerink Partners dropped their price target on shares of Keros Therapeutics from $30.00 to $23.00 and set an “outperform” rating for the company in a research note on Tuesday, August 4th. Four analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $20.50.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.